Company intelligence / Profile preview

Euglena

Minato-ku, Tokyo, Japan

Ownership: Private
Employees: ~846
Development stage: Other

Overview

Euglena has achieved commercial production and sales for functional foods, health supplements, and cosmetics based on its proprietary mass cultivation of Euglena microalgae; research suggests paramylon (a β-glucan) may have benefits in immune balance and cancer suppression, but most clinical results are pre-clinical or early-stage[2][3].

Therapeutic areas: ImmunologyGastroenterologyMetabolic DisordersOtherDermatologyOncology
Modalities: Microbial therapyLive biotherapeutic product therapyFunctional food ingredientNutraceutical
Industry: Non-Drug Biotech

Partnerships

Eni (joint biofuel refinery study, Malaysia)[1]PETRONAS (biofuel partnership)[1]Next Meats (alternative meat/cosmeceutical joint development)[1]Grameen Group (Bangladesh nutrition/social business)[3]

Beyond the preview

Go deeper on Euglena.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Euglena.

Explore the full profile